Johnson & Johnson filings document the regulatory record for a New Jersey healthcare company with Innovative Medicine and MedTech operations. Recent 8-K reports cover sales and earnings releases, dividend actions, annual meeting voting results and other material corporate events.
The company’s proxy materials describe board elections, executive compensation votes and shareholder governance matters. Its exchange-registered securities include JNJ common stock and multiple NYSE-listed notes with maturities extending across the company’s long-term debt profile.
Johnson & Johnson (JNJ), acting as the institutional investment manager, reported 15 Form 13F information-table entries with a total value of $761,691,304, rounded to the nearest dollar. Johnson & Johnson Innovation - JJDC, Inc. is named as the report’s one other included manager. The report type is a 13F holdings report.
Johnson & Johnson (JNJ) reported fiscal third-quarter sales of $25.399 billion, up 5.9% from $23.993 billion a year earlier. Net earnings were $210 million, versus $5.152 billion, and diluted earnings per share were $0.09 versus $2.12. For the nine months ended September 27, 2026, sales were $74.771 billion versus $69.629 billion, net earnings were $10.979 billion versus $21.688 billion, and net cash flows from operating activities were $18.850 billion versus $17.221 billion.
Fiscal third-quarter sales were $16.757 billion in Innovative Medicine and $8.642 billion in MedTech. Earnings included a $5.5 billion charge related to a proposed resolution of talc ovarian litigation. The proposed agreement is conditioned, among other things, on express participation by at least 95% of remaining claims and does not impact the ongoing mesothelioma docket.
JNJ completed its acquisition of Firefly Bio on July 29, 2026, for approximately $1.0 billion in cash. It made total initial payments of $0.8 billion under strategic agreements and a collaboration with Sail Biomedicines, and was granted an exclusive option to acquire Sail for approximately $2.6 billion. JNJ expects its planned Orthopaedics separation to be completed in mid-2027.
Johnson & Johnson reported third-quarter 2026 sales of $25.399 billion, up 5.9% from a year earlier; operational sales growth was 6.0%. GAAP net earnings were $210 million and diluted EPS was $0.09, down 95.9% and 95.8%, respectively. The company said EPS reflected a one-time special charge for the proposed talc litigation resolution, the Firefly Bio acquisition and Sail Biomedicines collaboration. Adjusted net earnings were $6.339 billion, down 6.8%, and adjusted diluted EPS was $2.59, down 7.5%.
Johnson & Johnson raised its 2026 guidance: estimated reported sales are $101.0 billion–$101.4 billion, with a $101.2 billion midpoint, and adjusted diluted EPS is $11.05–$11.15, with an $11.10 midpoint. The adjusted EPS midpoint increased by $0.06, corresponding to 2.9% growth at the midpoint. Innovative Medicine sales rose 7.7% to $16.757 billion, while MedTech sales rose 2.5% to $8.642 billion. During the quarter, the company completed its Firefly Bio acquisition; it also reported FDA approval of IMAAVY for warm autoimmune hemolytic anemia and market authorization for its OTTAVA robotic surgical system.
JOHNSON & JOHNSON (JNJ) director Daniel E. Pinto reported an acquisition of 113.098 Deferred Share Units (DSUs) on September 8, 2026 as a grant/award under the company's Amended and Restated Deferred Fee Plan for Directors. These DSUs are settled in cash upon termination of his directorship and each DSU reflects the fair market value of one share of common stock at settlement. After this award and related dividend equivalents, Pinto holds a total of 2,445.177 DSUs directly. No Rule 10b5-1 trading plan is reported.
JOHNSON & JOHNSON (symbol: JNJ) is the issuer of record for a Form 4 filing submitted to the SEC. Woods Eugene A. reported acquisition or exercise transactions in this Form 4 filing.
JOHNSON & JOHNSON (JNJ) reported that director Eugene A. Woods received a grant of 135.717 Deferred Share Units (DSUs) on September 8, 2026 as part of his deferred cash retainer under the company’s Deferred Fee Plan for Directors, bringing his directly held DSUs to 6,578.771.
The DSUs, each linked in value to one share of common stock, will be settled in cash when his service as a director ends and include dividend equivalent rights that accrue based on Johnson & Johnson’s quarterly dividends.
JOHNSON & JOHNSON (symbol: JNJ) is the issuer of record for a Form 4 filing submitted to the SEC. HEWSON MARILLYN A reported acquisition or exercise transactions in this Form 4 filing.
JOHNSON & JOHNSON (JNJ) reported that director Marillyn A. Hewson received a grant of 180.956 Deferred Share Units (DSUs) on September 8, 2026 as a deferred cash retainer under the company’s Deferred Fee Plan for Directors. After this award, she holds 16,049.417 DSUs directly.
The DSUs, including associated dividend equivalent rights, are to be settled in cash upon termination of her directorship, with each DSU tied to the fair market value of one share of Johnson & Johnson common stock on the business day prior to settlement.
JOHNSON & JOHNSON (JNJ) executive Timothy Schmid, EVP and Worldwide Chair of MedTech, reported exercising employee stock options and selling the resulting common shares on September 2, 2026. He exercised options for 11,070 shares with an exercise price of $131.94 per share and for 22,527 shares with an exercise price of $151.41 per share, both granted under the company’s Long-Term Incentive Plan and expiring in 2029 and 2030, respectively. He acquired an equal number of common shares from these exercises and then sold 11,070 shares and 22,527 shares of common stock the same day at a reported price of $274.74 per share, resulting in a net sale of 33,597 shares. Indirect holdings reported as of the most recent plan reporting date include 758 shares through a 401(k) plan and 46 shares through an employee stock ownership plan. No Rule 10b5-1 trading plan is indicated.
JOHNSON & JOHNSON (JNJ) is the issuer of common stock that Timothy Schmid plans to sell under Rule 144. A notice was filed for the proposed sale of 33,597 shares of J&J common stock through Fidelity Brokerage Services LLC, with an aggregate market value of about $9.23 million, with a proposed sale date of September 2, 2026. The shares are to be issued from a stock option exercise with the issuer and settled in cash.
JOHNSON & JOHNSON (JNJ) has an initial insider ownership report from Thomas Cavanaugh, EVP WW Chair, Innovative Med. The filing lists existing equity awards and stock holdings rather than new transactions. Reported positions include several employee stock option grants on common stock, with exercise prices ranging from $151.41 to $243.45 per share and expiration dates between 2030 and 2036, plus multiple tranches of restricted share units that convert into common stock on a one-for-one basis as they vest. Cavanaugh also reports direct ownership of 71 Johnson & Johnson common shares and 428 shares held indirectly through a 401(k) plan.
JOHNSON & JOHNSON (JNJ) executive Jennifer L. Taubert (EVP, WWC. Innovative Medicine) reported an exercise-and-sale transaction involving 15,000 shares. She exercised 15,000 Employee Stock Options to acquire 15,000 shares of Common Stock at $115.67 per share, then sold 15,000 shares of Common Stock at a weighted average price of $263.36 per share in trades between $263.30 and $263.48. Following the option exercise, she held 28,712 derivative securities (stock options) of the issuer directly.